{"type":"trials","record":{"id":41662,"source_id":"clinicaltrials-gov","external_id":"NCT04932980","title":"Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD","brief_summary":"The currently widely established and preferred protocol for the treatment of wet age-related macular degeneration includes a loading phase of three monthly injections without interim adaptation or treatment according to disease activity, thereafter following a T\\&E strategy with treatment adaptation in increments of 2-4 weeks according to disease activity. Based on pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this prospective explorative study is to test whether an early extension of treatment intervals without a loading phase is an option without compromising functional outcomes. Based on a superiority of Afl compared to Ran with regard to achieving a dry retina after one year and based on studies, but in the absence of real-life experience with Bro, it seems of interest to test how far Afl and Bro are comparable in terms of their potential to extend the treatment intervals over 12 months, the time to dryness of the retina, and number of injections. Also, it is of high clinical relevance to demonstrate efficacy with longer initial treatment intervals compared to the current possibly over-treating loading-phase with three four-weekly injections.","overall_status":"Active Not Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Berner Augenklinik","enrollment":80,"countries":["Switzerland"],"start_date":"2022-05-09","completion_date":"2028-03-01","last_update_date":"2025-12-08","source_url":"https://clinicaltrials.gov/study/NCT04932980","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"SPARROW","age_range":"50 Years","comparator":"Aflibercept ® rapid treatment extension (T&E); Brolucizumab ® rapid treatment extension (T&E)","organization":"Berner Augenklinik","interventions":["Aflibercept","Brolucizumab","early treat and extend (T&E)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of injections given until week 52 — 52 weeks","Injections until week 104 — 104 weeks","Number of treatment failures — 52 weeks","Number of treatment failures — 104 weeks","Time until drying of retina — 52 weeks","Time until drying of retina — 104 weeks","portion of eyes without disease activity — 52 weeks","portion of eyes without disease activity — 104 weeks","eyes under treatment intervals of ≥12 weeks — 52 weeks","eyes under treatment intervals of ≥12 weeks — 104 weeks","Change in visual acuity — 52 weeks","Change in visual acuity — 104 weeks","Change in central subfield thickness (CST) — 52 weeks","Change in central subfield thickness (CST) — 104 weeks","Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters — 52 weeks","Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters — 104 weeks","Maximal treatment interval extension — 52 weeks","Maximal treatment interval extension — 104 weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Aflibercept","Brolucizumab","early treat and extend (T&E)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04932980","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-05-09 to 2028-03-01","comparator":"Aflibercept ® rapid treatment extension (T&E); Brolucizumab ® rapid treatment extension (T&E)","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.849Z","intervention":["Aflibercept","Brolucizumab","early treat and extend (T&E)"],"participants":80,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of injections given until week 52 — 52 weeks","Injections until week 104 — 104 weeks","Number of treatment failures — 52 weeks","Number of treatment failures — 104 weeks","Time until drying of retina — 52 weeks","Time until drying of retina — 104 weeks","portion of eyes without disease activity — 52 weeks","portion of eyes without disease activity — 104 weeks","eyes under treatment intervals of ≥12 weeks — 52 weeks","eyes under treatment intervals of ≥12 weeks — 104 weeks","Change in visual acuity — 52 weeks","Change in visual acuity — 104 weeks","Change in central subfield thickness (CST) — 52 weeks","Change in central subfield thickness (CST) — 104 weeks","Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters — 52 weeks","Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters — 104 weeks","Maximal treatment interval extension — 52 weeks","Maximal treatment interval extension — 104 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41662","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}